GlassScriptPhysician profile
Marshil Bullard Locklear
NPI 1053897611
$3,958.13
in general payments reported to CMS, 2019-2025
25 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $851 · 2023: $458 · 2024: $664 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,839.20 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $437.73 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $344.98 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $272.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.92 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $145.71 | 2024-2025 | Nuzyra, Xhance |
| Amgen INC. | $125.93 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $91.71 | 2021-2025 | |
| Revance Therapeutics, INC. | $60.95 | 2025 | Daxxify |
| Ironwood Pharmaceuticals, INC | $60.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $48.32 | 2021 | |
| Insulet Corporation | $46.66 | 2025 | Omnipod |
| Corcept Therapeutics | $39.24 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.95 | 2024-2025 | Jardiance |
| Astellas Pharma US INC | $35.79 | 2025 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.79 | 2024 | Arexvy, Shingrix |
| Mannkind Corporation | $22.60 | 2024 | |
| Ardelyx, INC. | $21.99 | 2025 | Ibsrela |
| Abbott Laboratories | $19.56 | 2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $18.76 | 2023 | |
| Xeris Pharmaceuticals, INC. | $17.67 | 2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $16.15 | 2022 | |
| Exact Sciences Corporation | $15.68 | 2025 | Cologuard Collection Kit |
| Organon LLC | $8.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $5.80 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshil Locklear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.